294 related articles for article (PubMed ID: 34884561)
1. Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression.
Piao XM; You C; Byun YJ; Kang HW; Noh J; Lee J; Lee HY; Kim K; Kim WT; Yun SJ; Lee SC; Kang K; Kim YJ
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884561
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.
Kim WJ; Kim EJ; Kim SK; Kim YJ; Ha YS; Jeong P; Kim MJ; Yun SJ; Lee KM; Moon SK; Lee SC; Cha EJ; Bae SC
Mol Cancer; 2010 Jan; 9():3. PubMed ID: 20059769
[TBL] [Abstract][Full Text] [Related]
3. A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer.
Piao XM; Kang HW; Jeong P; Byun YJ; Lee HY; Kim K; Seo SP; Kim WT; Lee JY; Ha YS; Choi YH; Moon SK; Yun SJ; Kim WJ
Urol Oncol; 2021 Apr; 39(4):237.e21-237.e29. PubMed ID: 33339725
[TBL] [Abstract][Full Text] [Related]
4. Dynamic expression changes between non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.
Zhao YG; Shi BY; Qian YY; Bai HW; Xiao L; He XY
Tumori; 2014; 100(6):e273-81. PubMed ID: 25688510
[TBL] [Abstract][Full Text] [Related]
5. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
[TBL] [Abstract][Full Text] [Related]
6. STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
Taber A; Park Y; Lelo A; Prip F; Xiao J; Berry DL; Chaldekas K; Jensen JB; Philips G; Kim JS; Harris BT; Dyrskjøt L; Waldman T
Urol Oncol; 2021 Jul; 39(7):438.e1-438.e9. PubMed ID: 33712344
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer.
Boegemann M; Krabbe LM
Mini Rev Med Chem; 2020; 20(12):1133-1152. PubMed ID: 27173513
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer.
Iliev R; Kleinova R; Juracek J; Dolezel J; Ozanova Z; Fedorko M; Pacik D; Svoboda M; Stanik M; Slaby O
Tumour Biol; 2016 Oct; 37(10):13385-13390. PubMed ID: 27460088
[TBL] [Abstract][Full Text] [Related]
9. The clinical and prognostic value of miR-9 gene expression in Tunisian patients with bladder cancer.
Setti Boubaker N; Cicchillitti L; Said R; Gurtner A; Ayed H; Blel A; Karray O; Essid MA; Gharbi M; Bouzouita A; Rammeh Rommeni S; Chebil M; Piaggio G; Ouerhani S
Mol Biol Rep; 2019 Oct; 46(5):4743-4750. PubMed ID: 31214962
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer.
Wu S; Nitschke K; Worst TS; Fierek A; Weis CA; Eckstein M; Porubsky S; Kriegmair M; Erben P
J Exp Clin Cancer Res; 2020 Dec; 39(1):288. PubMed ID: 33334367
[TBL] [Abstract][Full Text] [Related]
11. Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.
Franco R; Zappavigna S; Gigantino V; Luce A; Cantile M; Cerrone M; Facchini G; Perdonà S; Pignata S; Di Lorenzo G; Chieffi S; Vitale G; De Sio M; Sgambato A; Botti G; Yousif AM; Novellino E; Grieco P; Caraglia M
J Exp Clin Cancer Res; 2014 Jun; 33(1):48. PubMed ID: 24893613
[TBL] [Abstract][Full Text] [Related]
12. ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression.
Papadimitriou MA; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3075-3087. PubMed ID: 31595333
[TBL] [Abstract][Full Text] [Related]
13. Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer.
Silvers CR; Liu YR; Wu CH; Miyamoto H; Messing EM; Lee YF
Oncotarget; 2016 Apr; 7(17):23335-45. PubMed ID: 26981774
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
Rinaldetti S; Wirtz R; Worst TS; Hartmann A; Breyer J; Dyrskjot L; Erben P
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1701-1709. PubMed ID: 29959570
[TBL] [Abstract][Full Text] [Related]
15. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
16. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
[TBL] [Abstract][Full Text] [Related]
17. Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.
Abdelrahman AE; Rashed HE; Elkady E; Elsebai EA; El-Azony A; Matar I
Ann Diagn Pathol; 2019 Apr; 39():42-52. PubMed ID: 30684846
[TBL] [Abstract][Full Text] [Related]
18. Utility of SAM68 in the progression and prognosis for bladder cancer.
Zhang Z; Yu C; Li Y; Jiang L; Zhou F
BMC Cancer; 2015 May; 15():364. PubMed ID: 25944080
[TBL] [Abstract][Full Text] [Related]
19. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
[TBL] [Abstract][Full Text] [Related]
20. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]